Skip to main content
. 2018 May 8;38(3):BSR20171383. doi: 10.1042/BSR20171383

Figure 4. K562 imatinib resistant cells were sensitive to glycolysis inhibition.

Figure 4

(A) K562 or KU812 imatinib sensitive and resistant cells were cultured with low glucose RPMI-1640 medium for 24 or 48 h. The cell viabilities were measured by MTT assay. (B) K562 or KU812 imatinib sensitive and resistant cells were cultured with low glucose RPMI-1640 medium for 48 h. Cells were fixed and stained by DAPI. (C) K562 or KU812 imatinib sensitive and resistant cells were treated with 2-DG for 24 h, followed by the measurements of cell viability by MTT assay and (D) Caspase-3 activity assay. (E) K562 or KU812 imatinib sensitive and resistant cells were treated with Oxamate for 48 h, followed by the measurements of cell viability by MTT assay and (F) Caspase-3 activity assay. The results are presented as mean ± S.D. of triplicates from each of three independent experiments. *P <0.05; **P <0.01; ***P <0.001.